A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (greater than or equal to 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

Most Recent Events

31 Jan 2024 Planned End Date changed from 19 Jan 2024 to 30 Jan 2025.
02 Feb 2023 Planned End Date changed from 19 Jan 2023 to 19 Jan 2024.
17 Jun 2022 Results meta-analysis of randomized controlled trials from NCT0101006, NCT01886872, NCT01056510, and NCT03336333, presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight